Research Grade Luspatercept (DHB63001)

Research Grade Luspatercept (DHB63001)

一、中文名称：Research Grade Luspatercept (DHB63001)，研究级Luspatercept类似物

 

二、产品描述

Luspatercept (ACE-536) 是一种重组修饰的 ActRIIB 融合蛋白，可与转化生长因子 β 超家族配体结合。Luspatercept 增加红细胞数量，促进红细胞前体成熟。Luspatercept 与 GDF11 结合，抑制 Smad2/3 信号通路。Luspatercept 可用于贫血的研究。。

 

三、产品详情

名称：Research Grade Luspatercept (DHB63001)

别名：ACE-536,luspatercept–aamt, CAS: 1373715-00-4

货号：DHB63001

表达系统：Mammalian Cells

种属反应性：Human

同种型：Fusion - [ACVR2B (activin A receptor type 2B, ActR-IIB, ActRIIB)]2 - IGHG1 Fc (Fragment constant)

靶标：GDF11, BMP-11, BMP11, Growth/differentiation factor 11, GDF-11, Bone morphogenetic protein 11

浓度：7 mg/ml

内毒素水平：Please contact with the lab for this information.

纯度：>95% as determined by SDS-PAGE.

纯化方式：Protein A/G purified from cell culture supernatant.

Accession号：O95390

克隆号：Luspatercept

应用：Research Grade Biosimilar

状态：Liquid

保存溶液：0.01M PBS, pH 7.4.

稳定性和存储：Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

 

四、参考文献：

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.PMID:31914241

Luspatercept.PMID:37094054

Luspatercept.PMID:34648251

A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent beta-Thalassemia.PMID:32212518

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.PMID:37311468

Luspatercept: First Approval.PMID:31939073

Luspatercept in Myelodysplastic Syndromes: Who and When?PMID:32089218

Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies.PMID:38555469

Luspatercept in the treatment of lower-risk myelodysplastic syndromes.PMID:33511859

Luspatercept.PMID:32809470

Luspatercept for the treatment of anaemia in non-transfusion-dependent beta-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.PMID:36007538

Management of luspatercept therapy in patients with transfusion-dependent beta-thalassaemia.PMID:37037668

Luspatercept for beta-thalassemia: beyond red blood cell transfusions.PMID:34404288

详情请咨询Antibodysystem中国授权总代理-武汉佰乐博生物技术有限公司

 

武汉佰乐博生物技术有限公司作为法国Antibodysystem品牌亚洲区授权总代理。提供近3万种蛋白、抗体等核心生命科学试剂，旨在为生命科学科研工作者提供专业、全面、可靠的试剂产品。

试剂 | 耗材 | 定制 | 实验服务 | 供应链

免费热线：027-65279366 /18108604356